Cocrystal Pharma, Inc. (COCP)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.99
- As of
Kresmion compiles this page from COCP's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Cocrystal Pharma, Inc. (COCP): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-09.
See the full COCP dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for COCP on one page. Preview it with sample data, then open it live with a free account.
Preview the COCP dossierActive events for COCP
- mediumEarnings below estimates
Q2-2026: Missed consensus by 36.7%, EPS $-0.23 vs $-0.1683 estimate
- medium13F: new position
CITADEL ADVISORS LLC new position in COCP
- medium13F: new position
TWO SIGMA INVESTMENTS, LP new position in COCP
- mediumEarnings above estimates
Q2-2025: Beat consensus by 34.6% - EPS $-0.2 vs $-0.306 estimate
- mediumEarnings below estimates
Q1-2026: Missed consensus by 11.1% - EPS $-0.17 vs $-0.153 estimate
FREE, NO ACCOUNT
Every event on COCP, as it fires
You are seeing 5 of 8 events recorded on COCP since 2026-05-29.
The five above landed across 3 days. The other 3 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in COCP (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 19188J409 · 2026Q2 | $189K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 19188J409 · 2026Q2 | $184K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 19188J409 · 2026Q2 | $47K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, COCP
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
COCP against its peers
COCP's return on equity of -139.5% ranks in the 34th percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | COCP | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 789000 | n/a | 11 |
| Operating margin | n/a | -1488.2% | n/a | 8 |
| Net margin | n/a | -594.6% | n/a | 9 |
| Return on equity | -139.5% | -114.3% | 34 | 15 |
Peers (20): BYSI, NEUP, QNRX, PVCT, KYNB, MCRB, JSPR, AKTX, CNTX, MRKR, NCEL, DYAI, PLUR, IMMP, ALLR, ATOS, GUTS, NXTC, INTI, BCDA. Left out: SPRC (period gap), PLRZ (no annual filing), FNCHQ (period gap), QNTM (no annual filing), HOOK.D (period gap). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (COCP: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow COCP on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to COCP for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.